NCT02113982: A trial that was reported late by Stemline Therapeutics, Inc.
This trial has reported, although it was 360 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02113982 |
|---|---|
| Title | Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 30, 2014 |
| Completion date | Feb. 1, 2020 |
| Required reporting date | Jan. 31, 2021, midnight |
| Actual reporting date | Jan. 27, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 360 |